Drug Trial Radar · NCT06093841
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Nov 3, 2023
Primary completion
Jan 21, 2024
Study completion Nov 4, 2029
Sponsor
- Lead sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.
Conditions
- Lymphoma, Large B-Cell, Diffuse
- Follicular Lymphoma Grade 3B
- High-grade B-cell Lymphoma
- Mediastinal B-Cell Diffuse Large Cell Lymphoma
Interventions
Relmacabtagene AutoleucelBiological
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
FludarabineDrug
Administered according to package insert
CyclophosphamideDrug
Administered according to package insert
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR at 3 monthTime frame: 3 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Jiangsu Provincial People's Hospital
Nanjing, China
Sun Yat-sen University Cancer Hospital
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Shandong Cancer Hospital
Jinan, Shandong, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, Shanghai Municipality, China
Institute of Hematology&Hospital of Blood Disease CAMS
Tianjin, Tianjin Municipality, China
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.